Cabaletta Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CABA research report →
Companywww.cabalettabio.com
Cabaletta Bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
- CEO
- Steven A. Nichtberger
- IPO
- 2019
- Employees
- 161
- HQ
- Philadelphia, PA, US
Price Chart
Valuation
- Market Cap
- $322.49M
- P/E
- -2.14
- P/S
- 0.00
- P/B
- 3.63
- EV/EBITDA
- -1.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -131.58%
- ROIC
- -138.26%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-167,856,000 · -44.87%
- EPS
- $-1.64 · 29.91%
- Op Income
- $-172,241,000
- FCF YoY
- -46.31%
Performance & Tape
- 52W High
- $4.23
- 52W Low
- $1.26
- 50D MA
- $3.18
- 200D MA
- $2.56
- Beta
- 3.17
- Avg Volume
- 3.10M
Get TickerSpark's AI analysis on CABA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 26 | Das Arun | other | 175,000 |
| Mar 2, 26 | Gerard Michael | other | 175,000 |
| Mar 2, 26 | Binder Gwendolyn | other | 225,000 |
| Mar 2, 26 | Chang David J. | other | 225,000 |
| Mar 2, 26 | Nichtberger Steven | other | 674,000 |
| Mar 2, 26 | Marda Anup | other | 225,000 |
| Jan 21, 26 | Chang David J. | buy | 8,800 |
| Jan 21, 26 | Binder Gwendolyn | buy | 11,312 |
| Jan 21, 26 | Tomasello Shawn | buy | 22,725 |
| Jan 21, 26 | Gavel Steve | buy | 22,170 |
Our CABA Coverage
We haven't published any research on CABA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CABA Report →